Skip to main content

Table 2 The relationship between clinicopathological factors and plasma VEGF levels

From: Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

  

Plasma VEGF Levels, pg/mL

Characteristics

No. (%)

Median

25-75% Quartile

p Value

Age

    

   <60

79 (59)

267.4

169.5 - 454.0

0.465

   >60

55 (41)

262.7

146.6-385.4

 

Sex

    

   Male

121 (90.3)

264.0

154.0 - 392.6

0.151

   Female

13 (9.7)

338.4

262.0 - 459.4

 

Smoking

    

   Smokers

108 (80.6)

273.9

173.7 - 442.7

0.144

   Never-smokers

26 (19.4)

257.1

120.7 - 354.5

 

ECOG

    

   1

39 (29.1)

225.7

108.6 - 354.5

0.062

   2-3

95 (70.9)

282.0

182.3 - 446.0

 

Histology

    

   SCC

103 (76.9)

276.0

169.5 - 439.5

0.147

   ADC

31 (23.1)

262.0

132.3 - 338.4

 

Stage

    

   III

87 (64.9)

251.4

149.0 - 433.4

0.250

   IV

47 (35.1)

276.0

214.0 - 399.4

 

Tumor Size

    

   <3 cm

44 (32.8)

172.4

93.0 - 262.0

0.001

   >3 cm

90 (67.2)

339.9

218.0 - 484.5

 

T Factor

    

   T2-T3

66 (49.2)

270.9

149.0 - 379.0

0.653

   T4

68 (50.8)

263.0

157.6 - 439.7

 

N Factor

    

   N0-N1

65 (48.5)

245.7

121.4 - 360.7

0.082

   N2-N3

69 (51.5)

285.7

192.0-439.5

 

M Factor

    

   M0

87 (64.9)

251.4

149.0 - 433.4

0.250

   M1

47 (35.1)

276.0

214.0 - 399.4

 

Tobacco

    

   Yes

25 (18.7)

252.3

185.7 - 354.5

0.524

   No

109 (81.3)

267.4

154.0 - 433.4

 
  1. VEGF, vascular endothelial growth factor; ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; ADC, adenocarcinoma; T, tumor; N, node; M, metastasis